In recent years, the discovery of immune checkpoints such as PD-1, PD-L1 and CTLA4 and the development and application of corresponding immune checkpoint inhibitors have provided new options for the treatment of advanced liver cancer [34]. Here, PDCD1 is linked to liver cancer.